Skip to content

NYMOX PHARMACEUTICAL CORP

NYMXF · OTCM

CIK 1018735fmd_0YFJA6FKYS5TZS6H3PZK18Z0BNManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Jan 01, 2015 to Dec 31, 2025, 33 periods

AI-written

A model wrote this from the company's own SEC filings and our standardized facts. It is not reported fact, not an analyst's estimate, not a rating and not investment advice. Every claim shows what it rests on.

Loading